HL BioTherapeutics aims to apply our unique immunotherapy platform that functions like a T cell receptor, to treat multiple types of solid and liquid cancers. The scientific founders, Catherine Bollard and Eric Yvon, have clinical and technical experience in designing and delivering novel immunotherapies to patients. The advantage of the HL BioTherapeutics platform is the extremely high specificity for tumors due to targeting of a specific MHC-displayed peptide from SSX2 protein. This targeting platform may be commercialized as an engineered T cell or NK cell, or as a therapeutic antibody. Our most advanced preclinical data uses T cell therapy for acute myeloid leukemia.
